Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | OT |
HCP calling to state that they gave the MMR-II vaccine to an individual who has Multiple Sclerosis and has an unspecified autoimmune disease. After administering the MMR-II they were told the patient is also immunocompromised. HCP did not provide fur; they gave the MMR-II vaccine to an individual who has Multiple Sclerosis and has an unspecified autoimmune disease; This spontaneous report was received from a pharmacist and refers to a 36-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions included multiple sclerosis, and an unspecified autoimmune disease. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (M-M-R II) solution for injection (exact dose, dose number, route of administration, anatomical location, lot # and expiration date were not reported), for prophylaxis (Contraindicated product administered). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot# and expiration date were not reported). The reporter stated that after administering measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (M-M-R II) they were told the patient was also immunocompromised. The outcome of the event was not reported. The causal relationship between the event and the suspect vaccine reconstituted with the suspect sterile diluent (MERCK STERILE DILUENT) was not provided. Upon internal review, the event of immunocompromised was determined to be medically significant.
Autoimmune disorder; Multiple sclerosis
DILUENT MRK